Suppr超能文献

螺旋断层放疗联合全身放疗治疗伴有骨髓抑制的原发性皮肤淋巴瘤:一种相关不良事件。

Helical Skin Radiation Therapy Including Total Skin Radiation Therapy Using Tomotherapy for Primary Cutaneous Lymphoma With Bone Marrow Suppression as a Related Adverse Event.

机构信息

Department of Radiology, University of Tokyo Hospital, Hongo, Bunkyo-ku, Tokyo, Japan.

Department of Radiology, University of Tokyo Hospital, Hongo, Bunkyo-ku, Tokyo, Japan.

出版信息

Pract Radiat Oncol. 2021 May-Jun;11(3):e308-e321. doi: 10.1016/j.prro.2020.11.007. Epub 2021 Jan 10.

Abstract

PURPOSE

Total skin electron beam therapy (TSEBT) is useful for primary cutaneous lymphoma. However, helical skin radiation therapy (HSRT) using tomotherapy may avoid the complexity and uncertainty of TSEBT.

METHODS AND MATERIALS

All patients with primary cutaneous lymphoma who underwent HSRT at our hospital between June 2015 and July 2019 were investigated, including 7 patients registered in a clinical trial approved by an institutional review board (ID UMIN000022142). HSRT was performed in 3 partitioned skin areas: head and neck, trunk and arms, and legs.

RESULTS

A total of 24 patients with 53 skin areas (including 8 patients with 24 skin areas who had undergone sequential total skin irradiation), with a median follow-up time of 13 months (range, 2-50), were investigated. Twenty patients (83.3%) had mycosis fungoides (MF). For 41 of 53 (77.4%) cases, a dose of 20 Gy in 10 fractions was used. The overall response rate in the treated fields of each HSRT in patients with MF was 100%, including 38 (80.9%) complete response, 4 (8.5%) good partial response, and 5 (10.6%) partial response. Eight patients with MF who underwent sequential total skin irradiation showed a 100% complete response. For patients with MF, the median survival time after a first round of HSRT was 22 months (95% confidence interval [CI], 13.6-30.4 months), the median response duration of each HSRT was 5 months (95% CI, 3.67-6.32 months), and the median time to in-field reirradiation for each HSRT was 15 months (95% CI, 9.76-20.24 months). Bone marrow suppression (grade ≥3) often occurred (94.1%) with HSRT on trunk and arm skin. An early patient died of HSRT-caused grade 5 leukopenia.

CONCLUSIONS

HSRT targeting trunk and arm skin induced severe bone marrow suppression that led to a temporary palliative effect. TSEBT should still be considered standard treatment for primary cutaneous lymphoma covering the total body surface area.

摘要

目的

全身电子束治疗(TSEBT)对原发性皮肤淋巴瘤有效。然而,使用托姆治疗的螺旋皮肤放射治疗(HSRT)可能避免了 TSEBT 的复杂性和不确定性。

方法和材料

对 2015 年 6 月至 2019 年 7 月期间在我院接受 HSRT 的所有原发性皮肤淋巴瘤患者进行了调查,包括在机构审查委员会(ID UMIN000022142)批准的临床试验中登记的 7 例患者。HSRT 分为 3 个分区皮肤区域进行:头颈部、躯干和手臂、腿部。

结果

共调查了 24 例患者的 53 个皮肤区域(包括 8 例接受 24 个皮肤区域连续全皮肤照射的患者),中位随访时间为 13 个月(范围为 2-50)。20 例(83.3%)为蕈样真菌病(MF)。对于 53 例中的 41 例(77.4%),使用 20Gy/10 次的剂量。MF 患者每次 HSRT 治疗区域的总体缓解率为 100%,包括 38 例(80.9%)完全缓解、4 例(8.5%)良好部分缓解和 5 例(10.6%)部分缓解。8 例接受连续全皮肤照射的 MF 患者均获得 100%完全缓解。对于 MF 患者,首次 HSRT 后中位生存时间为 22 个月(95%置信区间[CI]:13.6-30.4 个月),每次 HSRT 的中位缓解持续时间为 5 个月(95%CI:3.67-6.32 个月),每次 HSRT 的中位再照射时间为 15 个月(95%CI:9.76-20.24 个月)。HSRT 对躯干和手臂皮肤常引起骨髓抑制(≥3 级)(94.1%)。1 例患者因 HSRT 引起的 5 级白细胞减少症死亡。

结论

针对躯干和手臂皮肤的 HSRT 引起严重骨髓抑制,导致暂时的姑息效果。全身电子束治疗(TSEBT)仍应被认为是覆盖全身表面积的原发性皮肤淋巴瘤的标准治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验